Quest Diagnostics Incorporated (DGX) fair value analysis
S&P 500 · Updated 2026-10-19
DGX price how computed
Forward Fair Value verdict
OvervaluedDGX is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $230.97
- Sector
- Healthcare
- 12-month range
- $173.49–$247.45
- Market cap
- $25.5B
- From 52-week high
- -6.7%
- Shares outstanding
- 110M
- Rank in Healthcare by discount to fair value
- #82 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Quest Diagnostics is a clinical laboratory services company that provides diagnostic testing, drug screening, and health and wellness services to patients, employers, hospitals, and physicians. The company operates through a network of patient service centers and laboratory facilities across the United States and select international markets.
DGX currently ranks #82 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $25.5B
- P/E (trailing)
- 22x
- Revenue (TTM)
- $11.6B
- Net margin
- 9.2%
- EPS (TTM)
- $10.64
- Gross margin
- 33.7%
- Debt / equity
- 0.85
- Revenue growth (3-yr avg)
- 10.9%
- Shares outstanding
- 110M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 42 · neutral
- 50-day average
- $237.43
- 200-day average
- $208.86
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $3.38 per share (4 payments)
- Yield on last price
- 1.46%
- Consecutive years of increases
- 14
- Last ex-dividend date
- 2026-10-06
- Last payment date
- 2026-10-21
Earnings how computed
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+11.0%)
2026-03 ▲ beat (+5.5%)
2025-12 ▲ beat (+2.5%)
2025-09 ▲ beat (+4.0%)
2025-06 ▲ beat (+1.9%)
2025-03 ▲ beat (+2.8%)
2024-12 ▲ beat (+2.3%)
2024-09 ▲ beat (+1.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 7 hold · 1 sell (17 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $251
- Target vs last price
- +8.7%
What our data shows for DGX
- Our model validated 17 trailing price-to-earnings windows for DGX, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $173.49–$247.45.
- The 14-day relative strength index sits at a neutral 42.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for DGX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent DGX news
TickrTrends' derived news-sentiment signal for DGX is currently leaning positive, computed from recent coverage.
- Quest Diagnostics (DGX): Is Rapid Test Growth Translating Into Better Customer Economics? (insidermonkey.com, 2026-10-20)
TickrTrends take: Quest Diagnostics operates in a healthcare sector where rapid test growth presents questions about underlying profitability and customer retention economics. Given TickrTrends' current overvalued assessment, investors focused on valuation should monitor whether the company's expansion in rapid testing is generating improved margins and customer lifetime value, or merely driving volume growth that masks stagnant unit economics. The efficiency of converting rapid test growth into durable competitive advantages and pricing power will be critical to determining if the current valuation is justified. - IHF: A Concentrated And Volatile ETF In Healthcare Providers (NYSEARCA:IHF) (seekingalpha.com, 2026-10-14)
TickrTrends take: DGX operates in the Healthcare sector where concentrated exposure through vehicles like IHF can amplify volatility and valuation risks. Given TickrTrends' current assessment that DGX is overvalued, investors tracking this healthcare provider should monitor whether sector-wide volatility in concentrated ETFs reflects broader pricing pressures affecting individual healthcare stocks. The concentration and volatility characteristics noted in healthcare provider funds may indicate that elevated valuations in this space warrant closer scrutiny of fundamental metrics relative to peer comparisons. - Labcorp (LH): Is Its Earnings Discount Worth the Growing Investment Bill? (insidermonkey.com, 2026-10-12)
TickrTrends take: Labcorp's elevated investment costs relative to its earnings discount present a valuation concern that aligns with TickrTrends' assessment that DGX is currently overvalued within the Healthcare sector. As diagnostic and laboratory service providers face pressure to maintain competitive positioning through increased capital expenditure, investors should monitor whether companies like DGX can demonstrate sufficient earnings growth to justify their current valuation multiples. The expanding investment requirements in this industry underscore why valuation discipline remains critical for Healthcare sector investors evaluating whether current stock prices reflect realistic growth prospects.
More DGX news
- Is Quest Diagnostics Stock Outperforming the Nasdaq? (finance.yahoo.com, 2026-09-22)
- Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run? (zacks.com, 2026-09-16)
What people are saying
Follow the DGX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is DGX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), DGX is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is DGX's TickrTrends verdict?
DGX's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does DGX compare to other Healthcare stocks?
DGX ranks #82 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is DGX overbought or oversold?
DGX's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does DGX pay a dividend?
Yes. DGX paid $3.38 per share over the last twelve months (4 payments), a 1.46% yield on TickrTrends' last price, and has raised the annual total for 14 consecutive years. The last ex-dividend date was 2026-10-06.
Does DGX usually beat earnings estimates?
Over its last 8 reported quarters DGX beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about DGX?
Of 17 analysts covering DGX, 9 rate it a buy, 7 a hold and 1 a sell - buy-leaning, with a consensus price target of $251 (+8.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
DGX vs ABBV · DGX vs AMGN · DGX vs AZTA · DGX vs BIO · DGX vs CRL